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Abstract
Background: Host determinants of HIV-1 viral tropism include factors from producer cells that affect the efficiency
of productive infection and factors in target cells that block infection after viral entry. TRIM5a restricts HIV-1
infection at an early post-entry step through a mechanism associated with rapid disassembly of the retroviral
capsid. Topoisomerase I (TOP1) appears to play a role in HIV-1 viral tropism by incorporating into or otherwise
modulating virions affecting the efficiency of a post-entry step, as the expression of human TOP1 in African Green
Monkey (AGM) virion-producing cells increased the infectivity of progeny virions by five-fold. This infectivity
enhancement required human TOP1 residues 236 and 237 as their replacement with the AGM counterpart residues
abolished the infectivity enhancement. Our previous studies showed that TOP1 interacts with BTBD1 and BTBD2,
two proteins which co-localize with the TRIM5a splice variant TRIM5δ in cytoplasmic bodies. Because BTBD1 and
BTBD2 interact with one HIV-1 viral tropism factor, TOP1, and co-localize with a splice variant of another, we
investigated the potential involvement of BTBD1 and BTBD2 in HIV-1 restriction.
Results: We show that the interaction of BTBD1 and BTBD2 with TOP1 requires hu-TOP1 residues 236 and 237, the
same residues required to enhance the infectivity of progeny virions when hu-TOP1 is expressed in AGM producer
cells. Additionally, interference with the expression of BTBD2 in AGM and human 293T target cells increased their
permissiveness to HIV-1 infection two- to three-fold.
Conclusions: These results do not exclude the possibility that BTBD2 may modestly restrict HIV-1 infection via
colocation with TRIM5 variants in cytoplasmic bodies.
Background
Upon entry into target cells, retroviruses undergo sev-
eral transformations to establish a productive infection
which include uncoating of the viral core, reverse tran-
scription, nuclear access, and integration of the viral
DNA into the host genome [1,2]. Factor(s) incorporated
into HIV-1 virions from producer cells and factor(s)
present in target cells determine viral tropism [3-10].
Topoisomerase I (TOP1) activity has been found to
be associated with HIV virions [11], and the species of
TOP1 expressed in virion producer cells has been
reported to significantly influence viral infectivity:
HIV-1 virions produced by African Green Monkey
(AGM) cells were 85-90% less infective to human cells
as compared to virions produced by human cells [7].
Shoya et al. reported that expression of human-TOP1,
but not AGM-TOP1, in HIV-1-producing AGM cells
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any medium, provided the original work is properly cited.increased the infectivity of progeny virions about five-
fold [7]. This enhancement to the infectivity of HIV-1
virions provided by the expression of hu-TOP1 in
AGM cells was dependent on hu-TOP1 residues E236
and N237, as replacement of these residues with their
AGM counterparts abolished the activity enhance-
ment. The infectivity enhancement was associated
with a four-fold greater copy number of HIV-1 DNA
in target cells [7]. In contrast to Old World monkey
producer cells, in human producer cells (293T) the
expression of hu-TOP1 only slightly increased viral
infectivity. Also, expression of AGM TOP1, or hu-
TOP1 with residues 236 and 237 replaced with the
AGM counterpart residues (i.e., E236D/N237S), in
human producer cells caused virions to have four-fold
less infectivity [7].
TRIM5a is a major factor that restricts HIV-1 infec-
tion of Old World monkey cells, and expression of
rhesus monkey TRIM5a in human cells confers potent
resistance to HIV-1 infection [8]. Conversely, interfer-
ence with TRIM5a expression in Old World monkey
cells relieves the block to HIV-1 infection [8]. The
TRIM family of proteins contains a tripartite motif
that includes RING, B-box 2 and coiled-coil (cc)
domains. Many TRIM proteins, including TRIM5a,
assemble into cytoplasmic structures [12]. We pre-
viously reported that a non-restricting splice variant of
TRIM5, TRIM5δ, localizes to cytoplasmic bodies
together with BTBD1 and BTBD2. BTBD1 and BTBD2
proteins interact with TOP1, share 80% amino acid
sequence identity with each other, and contain a BTB/
POZ domain and kelch-like and PHR-like regions
[13,14]. The BTBD/POZ domain mediates homo- and
hetero-dimerization and some BTB domains bind the
Cul3 ubiquitin ligase and select substrates for ubiquity-
lation [15-18]. The kelch repeat is a b-propeller struc-
ture that appears in numerous proteins as a protein-
protein interaction site. Our observations that the
BTBD1 and BTBD2 proteins physically interact with
one HIV-1 restriction factor, TOP1, and co-localize
w i t has p l i c ev a r i a n to fT R I M 5 a prompted us to inves-
tigate the potential involvement of BTBD1 and BTBD2
in restricting HIV infection.
Here we show that the same two hu-TOP1 residues
required for the enhancement of the infectivity of pro-
geny virions when hu-TOP1 is expressed in AGM pro-
ducer cells are also required for hu-TOP1 to bind
BTBD1 and BTBD2. We also show that interference
with the expression of BTBD2 modestly increases HIV-1
infection in both non-permissive AGM cells and permis-
sive 293T cells. These two observations together suggest
that BTBD2 may be linked to restriction of HIV-1
infectivity.
Methods
Cell Culture
African green monkey (COS-1), human adenocarcinoma
HeLa, and large T antigen expressing human embryonic
kidney (293T) cell lines were maintained in Dulbeco’s
MEM (DMEM) supplemented with 2 mM L-Glutamine,
10% fetal bovine serum, and penicillin/streptomycin.
TOP1 constructs, yeast two-hybrid and GST-pulldown
The amino terminus of hu-TOP1 was fused to the Tap
tag [19], producing TAP-TOPE236/N237 or TAP-
TOPD236/S237. These plasmids were transiently trans-
fected into HeLa cells, and the expressed TAP-TOP1
proteins were purified and used to determine that the
amino acid replacements had no effect on DNA relaxa-
tion activity (Data not shown). Two hybrid and GST-
pulldown assays were performed as previously described
and in the legend to Figure 1 [14].
Immunofluorescence
Cells on coverslips were fixed with 4% paraformaldehyde
for 10 min on ice and treated with 0.1% Triton X-100
for 10 minutes on ice. Fixed cells were blocked with
PBS containing 3% BSA for 1 hour at room temperature
before incubation with primary antibodies. Secondary
antibody incubations were at room temperature for 45
min. For detection of cytoplasmic bodies, cells were
reacted with rabbit anti-BTBD1 peptide antibody [13]
followed by Alexa Fluor 568 goat anti-rabbit IgG (Mole-
cular Probes). Coverslips were mounted using Prolong
Antifade kit (Invitrogen, Carlsbad CA). Fluorescence
images were obtained using an Olympus IX70 inverted
fluorescence microscope equipped with a Princeton
Instrument cooled CCD camera integrated with Scanaly-
tics IP-Lab software. For quantification of BTBD1/D2
cytoplasmic bodies, the acquired images were analyzed
using TIFFany 3 (Caffeine Software) and the cytoplasmic
bodies were quantified using Mathematica software
(Wolfram research).
BTBD1 and BTBD2 shRNA constructs
The pSIREN-RetroQ vector system (Clontech, Palo Alto
CA) was used to produce BTBD1 and BTBD2 specific
short hairpin shRNA (under the control of the human
U6 promoter). Target sequences within both BTBD1
(NM_025238) and BTBD2 (NM_017797) sequences
were identified and verified by BLAST analysis for their
specificity to BTBD1 and BTBD2, respectively. The pSI-
REN-BTBD1 (D1#3) shRNA vector contained the
BTBD1-specific target sequence CACTCAAAGGTCCA-
GATTC, and the pSIREN-BTBD2 (D2#7) shRNA vector
contained the BTBD2-specific target sequence AGGT-
CATCTTCTACACCTA. Oligonucleotides used to
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(S-luc) shRNA vectors were supplied by the manufac-
turer. ShRNA vectors were constructed by inserting the
annealed oligonucleotides into the linearized pSIREN-
RetroQ vector. The nucleotide sequence of all clones
was determined to confirm the expected insertions.
Silencing of BTBD1, BTBD2 and TRIM5a genes
Control (S-ve and S-luc), BTBD1 (D1#3) and BTBD2
(D2#7) shRNA constructs (16 μg) were transfected into
2×1 0
6 COS-1 cells per 10 cm dish using Lipofecta-
mine-2000 transfection reagent (Invitrogen, Carlsbad
CA) at a DNA (μg) to Lipofectamine™ 2000 (μl) ratio of
1:2.5. After 48 h to 72 h, cells expressing the shRNA
constructs were harvested, tested for reduced expression
of BTBD1 and BTBD2 by Northern blotting, and
reseeded prior to HIV-1-luc infection.
For silencing TRIM5a, small-interfering RNA (siRNA)
directed against TRIM5a,5 ’-GCCUUACGAAGUCU-
GAAACUU-3’ [8], was used. A non-specific control
siRNA, 5’-AUGAACGUGAAUUGCUCAAUU-3’ [8],
was included in the experiments. Both TRIM5a-specific
and non-specific control siRNAs were purchased from
Dharmacon RNA Technologies (Lafayette, CO). COS-1
cells (1 × 10
6) were transfected in 100-mm dishes with
15 nM siRNA and 30 μl of Lipofectamine RNAiMAX
(Invitrogen, Carlsbad CA). After 48 h to 72 h, cells were
harvested, tested for reduced expression of TRIM5a
mRNA by Northern blotting, and reseeded prior to
HIV-1-luc infection.
RNA isolation and Northern blotting
Cells were lysed with 1 ml of TriPure Isolation Reagent
(Roche, Indianapolis IN) and RNA was purified. Equal
amounts of total RNA (10-20 μg) were loaded for elec-
trophoresis on a 1% formaldehyde-agarose gel and
transferred to a nylon membrane. The membranes were
subsequently hybridized with gene specific,
32P-labeled,
random primed probes, and the amount of mRNA was
quantified on a beta counter.
Western Blot
Cells were lysed in buffer A (50 mM Tris, pH 8.0, 150
mM NaCl, 1.0% Nonidet P-40, 0.5% deoxycholate) and
protein concentrations were determined using BCA kit
(Pierce, Rockford IL). Equivalent amounts of protein
were resolved in Tris-glycine gels, transferred to PVDF
membrane, and probed with antibody generated
Figure 1 Two-hybrid and co-precipitation assays show the requirement for hu-TOP1 residues E236/N237 for binding BTBD1 and
BTBD2. A. The Proquest two hybrid system (Invitrogen) was used with clones as previously described [14]. The TOP1 cap domain [20] (aa 219-
433) with either human residues E236/N237 (TOP1-EN) or AGM residues D236/S237 (TOP1-DS; three independent clones designated subscript 1,
2 and 3) fused to the Gal4 DNA binding domain (BD) were expressed from the minus Leu selectable plasmid. BTBD1 (aa 82-525) and BTBD2 (aa
1-482) were expressed as Gal4 activating domain (AD) fusions from the minus Trp selectable plasmid. Yeast transformed with these plasmids or
with their parent plasmids without TOP1, BTBD1 or BTBD2 sequences (empty) were replica plated using three fold dilutions onto plates without
Leu and Trp (-Leu,-Trp) to detect the presence of the plasmids. To detect the two hybrid protein interactions, the yeast were replica plated onto
plates lacking Leu, Trp and His (and with 25 mM 3AT to adjust His selection stringency); plates lacking Leu, Trp and Ura (-Ura); or, plates lacking
Leu and Trp and containing 5-fluoorotic acid (FOA, a substrate of URA3 that is converted into a toxic compound). hu-TOP1E236/N237 (TOP1-EN)
shows interaction with BTBD1 and BTBD2 but three clones of hu-TOP1D236/S237 do not. B. GST-pulldown assay: GST fused to the cap domain of
hu-TOP1 (EN, duplicate lanes; DS, triplicate clones) on glutathione beads were incubated with cell extracts containing C-terminal regions of
BTBD1 (aa 186-482) and BTBD2 (aa 219-525). After incubation and washing, the bead pellets were processed for Western blots using polyclonal
antibody recognizing both BTBD1 and BTBD2. GST-capTOP1E236/N237 co-precipitates BTBD1 (p-BTBD1) and BTBD2 (p-BTBD2) but GST-
capTOP1D236/S237 does not. Immunostaining of GST-capTOP1 is with GST antibody (GST-TOP1-I/II). Lane 1 was loaded with 1/30
th of the extract
containing BTBD1 and BTBD2. C.A si n“B” but endogenous BTBD1 and BTBD2 enriched from 293T cells is detected using peptide antibodies
specific to each protein that were pulled down from extracts of 293T cells by GST-capTOP1E236/N237 but not by GST-capTOP1D236/S237. All
experimental results were reproduced in at least two replicate experiments.
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and BTBD2 (Figure 1B), peptides specific for BTBD1
or BTBD2 that do not cross-react (Figure 1C), hu-
TOP1 (rabbit F14; LAE Biotechnology Co., Ltd., Rock-
ville MD) or GST. The blots were developed using the
appropriate horseradish peroxidase-conjugated second-
ary antibodies and ECL reagent (Amersham, GE
Health, Piscataway NJ).
Reporter gene virus and Infection assays
Vesicular stomatitis virus (VSV) G glycoprotein pseudo-
typed retrovirus particles containing a luciferase reporter
gene were produced by cotransfecting 293T cells with
the HIV-1 derived backbone plasmid (pNL4-3 env
- Vpr
+
Luc) and a plasmid for VSV-G expression (pCG). COS-
1 cells transfected with shRNA constructs, siRNAs or
TOP1 expression constructs were seeded in 48-well
plates (20,000 cells/well), incubated for 48 hours and
subsequently inoculated with different amounts of VSV-
G pseudotyped, HIV-1 luciferase reporter gene encoding
virus (VSV-G/HIV-1/Luc). Cells were lysed 48 h post-
infection (0.1% Triton-X-100 in PBS) and the virus
infectivity was evaluated by measuring the luciferase
activity of the cell lysates using the Luciferase Assay Kit
(Promega, Madison WI) with a Fluoroskan Ascent
luminometer (Thermo Labsystems).
Results
E236 and E237 of TOP1 are required for interaction with
BTBD1 and BTBD2
In a previous study we used two hybrid and pulldown
assays together with deletion fragment mapping to
demonstrate the requirement for TOP1 residues 215 to
329 (15% of the 765 aa protein) for the physical
interaction with BTBD1 and BTBD2, two proteins
which co-localize with TRIM5δ [14]. This 115 amino
acid fragment of TOP1 contains residues E236 and
N237 previously shown by Shoya et al. to be key deter-
minants of species-specific tropism of HIV infection.
We therefore tested the requirement of these TOP1
residues for interaction with BTBD1 and BTBD2. We
compared the hu-TOP1 core domain [20] to the core
domain with residues E236 and N237 replaced with the
AGM counterpart residues (E236D/N237S) for ability to
interact with BTBD1 and BTBD2 using two-hybrid and
GST-pulldown assays. Replacement of hu-TOP1 resi-
dues E236/N237 with AGM residues D236/S237 abol-
ished the two-hybrid interactions (Figure 1A). For the
pull-down assay, we fused GST to an independently
folding domain of hu-TOP1 termed the cap domain
that consists of core subdomains 1 and 2 and includes
E236/N237 (GST-hu-TOP1cap). This fusion protein co-
precipitated purified BTBD1 and BTBD2 fragments, but
GST-hu-TOP1cap with E236D/N237S failed to co-preci-
pitate BTBD1 or BTBD2 (Figure 1B).
Next we tested whether GST-hu-TOP1cap could co-
precipitate endogenous BTBD1 and BTBD2 from HeLa
cell extracts. Our previous efforts to detect these pro-
teins on Western blots of whole cell lysates using anti-
bodies generated to major portions of the proteins or to
unique peptides were not successful, suggesting limited
amounts of the proteins in the cells. To test whether
GST-hu-TOP1cap could enrich for and co-precipitate
endogenous BTBD1 and BTBD2 cellular proteins, we
incubated HeLa cell extracts with GST-hu-TOP1cap or
GST-hu-TOP1cap having E236/N237 replaced with
AGM residues D236/S237. GST-hu-TOP1cap co-precipi-
tated proteins of about 60 kDa, which were recognized
by antibodies specific to BTBD1 or BTBD2, respectively,
and were not co-precipitated by GST-hu-TOP1cap with
AGM residues D236/S237 (Figure 1C). Thus, the two
residues of TOP1 required for enhancing the infectivity
of progeny virions [7] were also required for TOP1 to
physically interact with cellular BTBD1 and BTBD2.
Tranfection of BTBD1 and BTBD2 shRNA silencing
plasmids decreases target mRNAs and cytoplasmic bodies
detected with BTBD1-specific antibody
We investigated the potential involvement of BTBD1
and BTBD2 in restricting HIV-1 infection based on the
observations that: 1) BTBD1 and BTBD2 co-localize
with TRIM5δ [13], a splice variant of TRIM5a;2 )hu-
TOP1 residues E236/N237 are required for the infectiv-
ity enhancement provided to virions by the expression
of hu-TOP1 in AGM virion-producer cells; and, 3) these
same human residues are required for the physical inter-
action of hu-TOP1 with BTBD1 and BTBD2. We
depleted BTBD1 or BTBD2 using RNAi. Plasmids
expressing short hairpin RNA specific for BTBD1 or
BTBD2 and control RNA were transfected in COS-1
African green monkey kidney cells. Northern blotting
showed a 70-80% reduction of BTBD1 and BTBD2
mRNA in cells transfected with specific shRNA for
BTBD1 or BTBD2, respectively, as compared to untrans-
fected or vector controls (Figure 2A).
To evaluate the effect of RNA interference of BTBD1
and BTBD2 on their protein levels, we quantified cyto-
plasmic bodies stained with BTBD1-specific antibody in
COS-1 cells 72 hours after transfection of the silencer
plasmids. In cells transfected with only one specific
silencer shRNA construct, either against BTBD1 or
BTBD2, the average number of cytoplasmic bodies per
cell was similar to control cells. In cells transfected with
both shRNA silencer plasmids, the average number of
cytoplasmic bodies per cell was reduced by 40%, from
~3.8 to 2.2 (Table 1 and Figures 2B and 2C).
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Page 4 of 8Transfection of BTBD2 shRNA silencing plasmid increases
permissiveness to HIV-1 infection
We next evaluated the effect of the BTBD1 and BTBD2
shRNA plasmids transfected individually on permissive-
ness to HIV-1 infection in COS-1 cells. Cells transfected
with the BTBD2 shRNA plasmid were 2.5 to 3-fold
more permissive to HIV-1 infection (Figure 3A). In con-
trast, transfection of BTBD1 shRNA did not increase
permissiveness to infection (data not shown). For the
sake of comparison, we used the siRNA mediated
approach to deplete TRIM5a in COS-1 cells as done by
others [8,21-23]. Similar to their results, siRNA targeting
TRIM5 increased permissiveness to HIV-1 infection up
to 20 fold (Figure 3B), which is roughly eight-fold more
permissiveness than we observed in AGM cells trans-
fected with the BTBD2 shRNA plasmid.
Discussion
Shoya et al. reported that expression of hu-TOP1, but
not AGM-TOP1, in the AGM producer cells increased
infectivity of the progeny virus five-fold [7]. Only eight
amino acid residues differ between AGM-TOP1 and
hu-TOP1. Substitution of the human residues with the
AGM residues was used to identify the human residues
required for the infectivity enhancement. Only replace-
ment of glutamate-236 and asparagine-237 of hu-TOP1
with the corresponding conserved monkey residues
(aspartate and serine, respectively) abolished the infec-
tivity enhancement. E236 and N237 of hu-TOP1 are far
from the active site (Figure 4), solvent exposed, and
their replacement with the AGM counterparts (E236D/
N237S) did not affect DNA relaxation activity (data not
shown).
Shoya et al. reported that the enhanced infectivity of
HIV-1 virions, provided by expression of hu-TOP1,
but not AGM-TOP1 or E236D/N237S-hu-TOP1, was
not a consequence of the amount of virus produced,
the processing of Gag or Env, nor viral entry, but was
associated with a four-fold greater copy number of
HIV-1 DNA in human target cells. They additionally
showed expression of AGM-TOP1 or E236D/N237S-
hu-TOP1 in human virion producer cells acts in a
dominant negative manner to reduce the infectivity of
progeny virions [7].
Figure 2 COS-1 cells transfected with plasmids encoding shRNAs specific to BTBD1 and BTBD2 show reductions in the specific mRNAs
and cytoplasmic bodies stained with BTBD1-specific antibodies. A. Northern blot shows reduced levels of expression of BTBD1 and BTBD2
mRNA in COS-1 cells transfected with BTBD1 or BTBD2 specific silencer constructs. COS-1 cells were untransfected (Un) or transfected with the
negative control vector, pSIREN (S-ve), the pSIREN vector encoding Luciferase silencer (S-luc), pSIREN vector encoding BTBD1 shRNA (D1 #3) or
BTBD2 shRNA (D2 #7). 48 hours post-transfection, transiently transfected and untransfected (COS-1) cells were harvested for RNA isolation. The
Northern blot was hybridized with BTBD1 and BTBD2 specific probes. Equal amounts of RNA (10 μg) were loaded onto each lane as seen with
the b-actin specific probe. B. Representative immunofluorescence images showing cytoplasmic bodies in COS-1 cells transfected with pSIREN
negative control vector (S-ve), silencer constructs for BTBD1 or BTBD2, or both BTBD1 and BTBD2. Seventy-two hours post-transfection cells were
labeled with rabbit BTBD1-specific peptide antibody (#4358) followed by Alexa Fluor 568 goat anti-rabbit IgG (Molecular Probes). C.
Quantification of BTBD1/D2 cytoplasmic bodies. The acquired images were analyzed using TIFFany 3 (Caffeine Software) and the cytoplasmic
bodies were quantified using Mathematica software (Wolfram research).
Table 1 shRNA interference of both BTBD1 and BTBD2 reduces the number of cytoplasmic bodies
S-ve* sh-BTBD1 sh-BTBD2 sh-BTBD1 + sh-BTBD2
TOTAL cytoplasmic bodies 413 395 348 227
Total cells counted 110 104 103 105
Cytoplasmic bodies/cell 3.8 3.8 3.4 2.2
* vector control
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hu-TOP1 comprising 15% of the protein previously
shown to be required for binding BTBD1 and BTBD2.
Here we have shown that hu-TOP1 with replacements
of E236 and N237 with the AGM residues D236 and
S237 did not bind BTBD1 or BTBD2 in two-hybrid and
GST-pulldown assays. Thus, the two residues required
for hu-TOP1 expression in AGM producer cells to
enhance the infectivity of HIV-1 virions are also
required for the interaction with BTBD1 and BTBD2,
two proteins which co-localize with TRIM5g (unpub-
lished) and TRIM5δ [13].
We also found that depletion of BTBD2 in COS-1
cells increased their permissiveness to HIV-1 infection
by 2.5 to 3-fold. Similarly, in human embryonic kidney
293T cells, depletion of BTBD2 increased permissive-
ness to infection by 1.8 to 2.8-fold (data not shown).
For comparison, TRIM5a of AGM strongly restricts
HIV-1 infection [8,24,25] (~20-fold in our experiments,
Figure 3B), while human TRIM5a only modestly inhi-
bits HIV-1 infection by about 50% [8,25]. Our data
show that in both human and AGM cells, depletion of
BTBD2 only modestly increased permissiveness to
HIV-1 infection by about 2-3 fold. Thus, this modest
restriction involving BTBD2 did not require the high
level restriction provided by TRIM5a of Old World
primates.
BTBD1 and BTBD2 localize in cytoplasmic bodies
with each other [14] and interact with each other in two
hybrid assays (unpublished results). BTBD1 binds Cul3
in co-precipitation assays using bacterially purified pro-
teins, and flag-tagged BTBD1 bound the Cul3 N-term-
inal 197 aa in transfected 293T cells [15]. Cul-based and
other ubiquitin E3 ligases catalyze ubiquitin transfer to
s u b s t r a t ep r o t e i n sb yp o s i t i o ning their lysines for opti-
mal presentation to ubiquitin bound to the E2 active
site [26]. Some BTB domain proteins are involved in
selecting substrates for Cul3 ubiquitin ligases [15-18].
Figure 3 Permissiveness to HIV-1 infectivity increases in COS-1 cells transfected with BTBD2 silencer construct. A.C O S - 1c e l l s
transfected with silencer plasmids or controls were subsequently infected with VSV-G/HIV-1/Luc (p24 titer: 440 ng/ml): Uninfected COS-1 cells
(Cos1), pSIREN control (S-ve), pSIREN encoding Luciferase shRNA (S-luc), pSIREN encoding BTBD2 shRNA (D2 #7). Bold numbers above bars
represent actual average infectivity. B. HIV-1 infectivity in COS-1 cells transfected with either non-specific siRNA or TRIM5a specific siRNA. Bold
numbers above bars represent actual average infectivity data. Forty-eight hours post-transfection, transiently transfected and untransfected (COS-
1) cells were seeded onto 48-well plates at 20,000 cells/well) and inoculated 24 hours later with 5, 10 and 20 μl of VSV-G/HIV-1/Luc virus in
triplicate. Cells were lysed 48 hours after virus inoculation and luciferase activity in the lysates was measured. HIV-1 infectivity is represented as
average fold increase or decrease in luciferase activity relative to control Siren-ve (S-ve) cells (A) or cells transfected with non-specific siRNA (B).
Figure 4 hu-TOP1 residues E236/N237 in crystal structure. A.
Structure of TOP1 in covalent complex with topotecan (MMDB:
49892) shows active site (arrow), the cap region (core subdomains I
and II, [20]), and residues E236 and N237 (yellow) within the box. B.
Enlargement of boxed region in panel-A shows that E236 and N237
are solvent exposed.
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increased permissiveness to HIV-1 infection resulting
from BTBD2 silencing might in some way relate to the
co-localization of BTBD1 and BTBD2 with TRIM5 pro-
teins in cytoplasmic bodies or the involvement of
BTBD1 and BTBD2 with other factors that may influ-
ence permissiveness to HIV-1 infection [25]. BTBD1
and BTBD2 co-localize with TRIM5δ and TRIM5g,b u t
these variants lack the C-terminal B30.2 domain that
interacts directly with the viral capsid and determines
specificity for virus restriction [27-29]. TRIM5g and
TRIM5δ, possibly by hetero-multimerizing with
TRIM5a, can act dominant-negatively to inhibit the
viral restricting activity of TRIM5a [8,30].
Conclusions
The results presented here demonstrate that the interac-
tion of BTBD1 and BTBD2 with TOP1 requires residues
236 and 237 of hu- T O P 1 ,t h es a m er e s i d u e sr e q u i r e d
for hu-TOP1 when expressed in AGM virion producer
cells to enhance the infectivity of progeny virions. Inter-
ference with the expression of BTBD2 in either AGM or
human cells increased their permissiveness to HIV-1
infectivity two- to three-fold.
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